Latest filings (excl ownership)
6-K
Current report (foreign)
28 Mar 24
6-K
IPA Acquires the Carterra LSA® Instrument to Enhance Antibody Discovery and Bolster Its AI Developments
20 Mar 24
6-K
Current report (foreign)
14 Mar 24
6-K
Current report (foreign)
14 Mar 24
6-K
Current report (foreign)
7 Mar 24
6-K
Current report (foreign)
23 Feb 24
424B5
Prospectus supplement for primary offering
23 Feb 24
6-K/A
Current report (foreign) (amended)
15 Feb 24
6-K
Material Change Report
14 Dec 23
6-K
Current report (foreign)
14 Dec 23
6-K
Immunoprecise Antibodies LTD. 6-K
14 Dec 23
6-K
Immunoprecise Antibodies LTD. 6-K
8 Dec 23
424B5
Prospectus supplement for primary offering
7 Dec 23
6-K
Current report (foreign)
6 Dec 23
6-K
Immunoprecise Antibodies LTD. 6-K
6 Dec 23
6-K
Immunoprecise Antibodies LTD. 6-K
6 Dec 23
424B5
Prospectus supplement for primary offering
5 Dec 23
6-K
Immunoprecise Antibodies LTD. 6-K
27 Nov 23
6-K
Report of Voting Results
16 Nov 23
6-K
Immunoprecise Antibodies LTD. 6-K
13 Nov 23
6-K
BioStrand Unveils Groundbreaking Retrieval Augmented Generation (RAG)-Based LLM Platform Integrated with Patented HYFT Technology
25 Oct 23
6-K
Immunoprecise Antibodies LTD. 6-K
23 Oct 23
6-K
Current report (foreign)
20 Oct 23
6-K
Material Change Report
26 Sep 23
6-K
Current report (foreign)
25 Sep 23
6-K
Immunoprecise Antibodies LTD. 6-K
19 Sep 23
6-K
Statement of Executive Compensation
18 Sep 23
6-K
Current report (foreign)
14 Sep 23
6-K
Immunoprecise Antibodies LTD. 6-K
14 Sep 23
6-K
Material Change Report
12 Sep 23
6-K
The Company to host an earnings conference call via webcast
8 Sep 23
6-K
IPA appoints Barry A. Springer, Dirk Witters and Chris Buyse to the Board of Directors
5 Sep 23
6-K
Current report (foreign)
15 Aug 23
424B5
Prospectus supplement for primary offering
15 Aug 23
6-K/A
Current report (foreign) (amended)
14 Aug 23
6-K/A
Current report (foreign) (amended)
14 Aug 23
6-K
Immunoprecise Antibodies LTD. 6-K
9 Aug 23
EFFECT
Notice of effectiveness
17 Jul 23
6-K
Immunoprecise Antibodies LTD. 6-K
14 Jul 23
CORRESP
Correspondence with SEC
13 Jul 23